Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HUMANA INC
Report date April 21, 2022 · Filed April 21, 2022
Section 16 reporting ended · disclosed 2022-04-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Humana CommonSEC Table I · non-derivative | Direct | 2,044 |
Reported balance
Holding disclosure · report date 2022-04-21 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,044 F3: Includes 412 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/22. Award will be pro-rated based on number of months served on the board in the current year. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 17,687 |
Reported balance
Holding disclosure · report date 2022-04-21 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 17,687 F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until her resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 169 |
Reported balance
Holding disclosure · report date 2022-04-21 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 169 F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until her resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d). |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until her resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1).
F2: Director's dividend payment reinvested into stock units on vested and deferred stock units, deferred in accordance with the Plan until her resignation of services as a director at which time the deferred dividend stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule16(b)-3(d).
F3: Includes 412 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/22. Award will be pro-rated based on number of months served on the board in the current year.
OCLARO, INC.
Report date December 10, 2018 · Filed December 10, 2018
Section 16 reporting ended · disclosed 2018-12-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-12-10 transaction · row 1
1 source rowRow 1 · 2018-12-10 · Disposition to issuer · Disposed 292,133 · Balance 0 F1: Pursuant to Agreement and Plan of Merger, dated March 11, 2018 (the "Merger Agreement"), Lumentum Holdings Inc. ("Lumentum") acquired Oclaro, Inc. ("Oclaro") in a merger transaction (the "Merger") which became effective on December 10, 2018. At the effective time of the Merger, each share of Oclaro common stock converted into the right to receive, without interest, (a) $5.60 in cash and (b) 0.0636 of a share of common stock of Lumentum ("Merger Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2021-08-15 | Direct | 0 |
Reported balance
After 2018-12-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-10 · Disposition to issuer · Disposed 2,165 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 2,165 vested Oclaro stock options that were outstanding as of the Effective Date were cancelled and terminated and converted into the right to receive the Merger Consideration in respect of each Net Option Share (as defined in the Merger Agreement) covered by such cancelled options; provided that, in lieu of the Merger Consideration, any fractional Net Option Share (after aggregating all shares represented by all such cancelled options) was settled in cash based on the Cash Equivalent Consideration (as defined in the Merger Agreement) (the "Option Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2021-10-26 | Direct | 0 |
Reported balance
After 2018-12-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-10 · Disposition to issuer · Disposed 14,881 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 14,881 vested Oclaro stock options that were outstanding as of the Effective Time were cancelled and terminated and converted into the right to receive the Option Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to Agreement and Plan of Merger, dated March 11, 2018 (the "Merger Agreement"), Lumentum Holdings Inc. ("Lumentum") acquired Oclaro, Inc. ("Oclaro") in a merger transaction (the "Merger") which became effective on December 10, 2018. At the effective time of the Merger, each share of Oclaro common stock converted into the right to receive, without interest, (a) $5.60 in cash and (b) 0.0636 of a share of common stock of Lumentum ("Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 2,165 vested Oclaro stock options that were outstanding as of the Effective Date were cancelled and terminated and converted into the right to receive the Merger Consideration in respect of each Net Option Share (as defined in the Merger Agreement) covered by such cancelled options; provided that, in lieu of the Merger Consideration, any fractional Net Option Share (after aggregating all shares represented by all such cancelled options) was settled in cash based on the Cash Equivalent Consideration (as defined in the Merger Agreement) (the "Option Consideration").
F3: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 14,881 vested Oclaro stock options that were outstanding as of the Effective Time were cancelled and terminated and converted into the right to receive the Option Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 20:28 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 412 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000583 · form4.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,044 F3 · balance_after: Includes 412 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/22. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:13 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 403 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-21-000013 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,632 F3 · balance_after: Includes 403 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/21. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 18:11 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 1,246 | $399.89 | $498,262.94 |
DisclosureSEC source: 0000049071-20-000089 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229 F4 · price: All shares sold at price reported. F3 · balance_after: Includes 453 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/20. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:16 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-20-000008 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,475 F3 · balance_after: Includes 453 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan of which 100% is vesting on 12/31/20. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 19:41 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 588 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-19-000001 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,022 F3 · balance_after: Includes 588 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2019. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 17:00 UTC | OCLARO, INC. OCLR · Entity 161934 | Disposition to issuerStock Options (Right to Buy) · Derivative | 14,881 | Not disclosed Strike: $3.54 | Not disclosed |
DisclosureSEC source: 0001214659-18-007619 · marketforms-43209.xml · derivative · entry 3 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,881 shares Expires 2021-10-26 F3 · price: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 14,881 vested Oclaro stock options that were outstanding as of the Effective Time were cancelled and terminated and converted into the right to receive the Option Consideration. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 14,881 vested Oclaro stock options that were outstanding as of the Effective Time were cancelled and terminated and converted into the right to receive the Option Consideration. Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 17:00 UTC | OCLARO, INC. OCLR · Entity 161934 | Disposition to issuerStock Options (Right to Buy) · Derivative | 2,165 | Not disclosed Strike: $4.33 | Not disclosed |
DisclosureSEC source: 0001214659-18-007619 · marketforms-43209.xml · derivative · entry 2 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,165 shares Expires 2021-08-15 F2 · price: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 2,165 vested Oclaro stock options that were outstanding as of the Effective Date were cancelled and terminated and converted into the right to receive the Merger Consideration in respect of each Net Option Share (as defined in the Merger Agreement) covered by such cancelled options; provided that, in lieu of the Merger Consideration, any fractional Net Option Share (after aggregating all shares represented by all such cancelled options) was settled in cash based on the Cash Equivalent Consideration (as defined in the Merger Agreement) (the "Option Consideration"). F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, Ms. Peterson's 2,165 vested Oclaro stock options that were outstanding as of the Effective Date were cancelled and terminated and converted into the right to receive the Merger Consideration in respect of each Net Option Share (as defined in the Merger Agreement) covered by such cancelled options; provided that, in lieu of the Merger Consideration, any fractional Net Option Share (after aggregating all shares represented by all such cancelled options) was settled in cash based on the Cash Equivalent Consideration (as defined in the Merger Agreement) (the "Option Consideration"). Read SEC document |
| December 10, 2018 Filed Dec 10, 2018 17:00 UTC | OCLARO, INC. OCLR · Entity 161934 | Disposition to issuerCommon Stock | 292,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-18-007619 · marketforms-43209.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to Agreement and Plan of Merger, dated March 11, 2018 (the "Merger Agreement"), Lumentum Holdings Inc. ("Lumentum") acquired Oclaro, Inc. ("Oclaro") in a merger transaction (the "Merger") which became effective on December 10, 2018. At the effective time of the Merger, each share of Oclaro common stock converted into the right to receive, without interest, (a) $5.60 in cash and (b) 0.0636 of a share of common stock of Lumentum ("Merger Consideration"). Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:00 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 658 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000006 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434 F3 · balance_after: Includes 658 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2018. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 19:00 UTC | OCLARO, INC. OCLR · Entity 161934 | GrantCommon Stock | 18,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-17-006895 · marketforms-40172.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,133 F1 · kind: Represents a grant of restricted stock awards, which vests 100% on the first anniversary of the date of grant. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:18 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 3,305 | $207.52 | $685,863.18 |
DisclosureSEC source: 0000049071-17-000051 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 761 F4 · price: Shares sold at prices ranging from $206.00 to $208.19. F3 · balance_after: Includes 761 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2017. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:34 UTC | HUMANA INC HUM · Entity 1429 | GrantHumana Common | 761 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000005 · edgar.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,066 F3 · balance_after: Includes 761 restricted stock units pursuant to the annual Director's Fee Program representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2011 Plan of which 100% is vesting on 12/31/2017. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 18:45 UTC | OCLARO, INC. OCLR · Entity 161934 | GrantCommon Stock | 12,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-16-014907 · marketforms-37139.xml · nonDerivative · entry 1 PETERSON MARISSA T · CIK 0001220067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,371 F1 · kind: Represents a grant of restricted stock awards, which vests 100% on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.